Article
RUNX2 inhibition disrupts a PAX3::FOXO1-RUNX2 feed-forward loop and dismantles oncogenic gene programs in fusion-positive rhabdomyosarcoma
2025-07-24
Abstract excerpt
Fusion-positive rhabdomyosarcoma is an aggressive pediatric cancer of skeletal muscle lineage, with a 5-year overall survival of <30% for high-risk disease, and <8% when metastatic. The PAX3::FOXO1 fusion gene, resulting from t (2:13), is a signature driver of fusion-positive rhabdomyosarcoma, but similar to other transcription-factor based fusion genes in other cancers, not currently pharmacologically tractable...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- edae67f6-dfca-5ffd-bdbf-69c6cbdf1165
- DOI
- 10.1101/2025.07.21.665972
